PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (...
January 18 2018 - 1:01AM
REGULATED INFORMATION
GHENT, Belgium, 18 January 2018 -
Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced,
in accordance with Article 14 of the Belgian Law of 2 May 2007
regarding the publication of major shareholdings in issuers whose
securities are admitted to trading on a regulated market (the
"Transparency Law"), that it received a notification of
shareholdings from Bank of America Corporation on 15 and 16 January
2018.
Bank of America Corporation (taking into account
the holdings of its subsidiary undertakings) notified Ablynx that
it has crossed the 5% threshold and now holds 3,851,779 voting
securities of Ablynx, representing 5.15% of the 74,720,644
outstanding voting rights of Ablynx (versus 4.32% notified
previously on 2 November 2017).
The notifications contain the following
information:
- Reason for the notification:
- acquisition or disposal of voting securities or voting
rights
- acquisition or disposal of financial instruments that are
treated as voting securities
- Notification by: a parent undertaking or a controlling
person
- Persons subject to the notification requirement: Bank of
America Corporation, Wilmington, DE, USA
- Date on which threshold is crossed: 9 and 10 January
2018
- Threshold that is crossed: 5% of total voting rights and
5% of voting rights held through financial instruments
- Denominator: 74,720,644
- Details of the notification:
Name of select subsidiaries of Bank of America
Corporation |
% of voting rights |
% of voting rights held through financial instruments* |
Total of both |
Bank of America Corporation |
0.00% |
|
|
Merrill Lynch Pierce, Fenner & Smith Incorporated |
0.01% |
|
0.01% |
Bank of America, National Association |
0.02% |
|
0.02% |
Merrill Lynch Professional Clearing Corporation |
|
5.12% |
5.12% |
TOTAL |
0.03% |
5.12% |
5.15% |
* Type of financial instrument: "Right of Use"
- Chain of controlled undertakings through which the holding
is effectively being held: Bank of America, National
Association, Merrill Lynch Professional Clearing Corporation and
Merrill Lynch Pierce, Fenner & Smith Incorporated are
controlled by Bank of America Corporation. Bank of America
Corporation is not a controlled entity.
- Additional information: The right of use represent a
right of rehypothecation (not yet exercised) that Merrill Lynch
Professional Clearing Corporation has over stock held on behalf of
Prime Brokerage clients.
More
information is provided in the transparency notifications. Full
versions of the transparency notifications are available on Ablynx
website, under the section Investors.
The Articles of the Association of Ablynx NV
provide for shareholders notification threshold of 3%, 5% or a
multiple of 5% of the total number of existing voting rights.
About Ablynx
Ablynx is a biopharmaceutical company engaged in
the development of Nanobodies, proprietary therapeutic proteins
based on single-domain antibody fragments, which combine the
advantages of conventional antibody drugs with some of the features
of small-molecule drugs. Ablynx is dedicated to creating new
medicines which will make a real difference to society. Today, the
Company has more than 45 proprietary and partnered programmes in
development in various therapeutic areas including inflammation,
haematology, immuno-oncology, oncology and respiratory disease. The
Company has collaborations with multiple pharmaceutical companies
including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck &
Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo
Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is
headquartered in Ghent, Belgium. More information can be found on
www.ablynx.com.
For more information, please
contactAblynx:Dr Edwin MosesCEOt: +32 (0)9
262 00 07m: +32 (0)473 39 50 68e: edwin.moses@ablynx.com
Lies VannesteDirector Investor Relationst: +32 (0)9
262 01 37m: +32 (0)498 05 35 79 e:
lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media relations:Consilium Strategic
CommunicationsMary-Jane Elliott, Philippa Gardner, Sukaina
Virjit: +44 (0)20 3709 5700e:
ablynx@consilium-comms.com
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/0a4c0491-b7b8-4edc-984a-2d1205c24e9c